Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lot-to-lot consistency and non-inferiority study of a 10-valent pneumococcal conjugate vaccine versus Prevenar in infants
2005-003300-11Phase 3Completed
- Sponsor
- GSK
- Start
- Aug 2005
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of 10-valent pneumococcal conjugate vaccine, pneumococcal 7-valent conjugate vaccine and pertussis filamentous haemagglutinin in pneumococcal disease (4 arms), sponsored by GSK. Primary endpoints: Lot-to-lot consistency of the 10-valent pneumococcal conjugate vaccine and Non-inferiority versus Prevenar for febrile reactions. Started Aug 2005; status: completed.
02
Drugs
10-valent pneumococcal conjugate vaccinepneumococcal 7-valent conjugate vaccinepertussis filamentous haemagglutinin
03
Conditions
pneumococcal disease
Beyond the preview
Go deeper on 2005-003300-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-003300-11.